Abstract:Immune evasion contributes to cancer growth and progression. Cancer cells have the ability to activate different immune checkpoint pathways that harbor immunosuppressive functions. The programmed death protein 1 (PD-1) and programmed cell death ligands (PD-Ls) are considered to be the major immune checkpoint molecules. The interaction of PD-1 and PD-L1 negatively regulates adaptive immune response mainly by inhibiting the activity of effector T cells while enhancing the function of immunosuppressive regulatory T cells (Tregs), largely contributing to the maintenance of immune homeostasis that prevents dysregulated immunity and harmful immune responses. However, cancer cells exploit the PD-1/PD-L1 axis to cause immune escape in cancer development and progression. Blockade of PD-1/PD-L1 by neutralizing antibodies restores T cells activity and enhances anti-tumor immunity, achieving remarkable success in cancer therapy. Therefore, the regulatory mechanisms of PD-1/PD-L1 in cancers have attracted an increasing attention. This article aims to provide a comprehensive review of the roles of the PD-1/PD-L1 signaling in human autoimmune diseases and cancers. We summarize all aspects of regulatory mechanisms underlying the expression and activity of PD-1 and PD-L1 in cancers, including genetic, epigenetic, post-transcriptional and post-translational regulatory mechanisms. In addition, we further summarize the progress in clinical research on the antitumor effects of targeting PD-1/PD-L1 antibodies alone and in combination with other therapeutic approaches, providing new strategies for finding new tumor markers and developing combined therapeutic approaches.

Role of programmed death protein-1/programmed death ligands signaling pathway and the antibodies in the therapy of head and neck cancers

Engagement of Programmed Cell Death 1 and Its Ligands in Human Papillomaviurs Related Diseases

The current advances and future directions of PD-1/PD-L1 blockade in head and neck squamous cell carcinoma (HNSCC) in the era of immunotherapy

Progresses and Perspectives of Anti-PD-1/PD-L1 Antibody Therapy in Head and Neck Cancers

The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer

PD-1/PD-L1 pathway: current researches in cancer.

PD-1 and PD-L1 in cancer immunotherapy: clinical implications and future considerations

Current studies and future promises of PD-1 signal inhibitors in cervical cancer therapy

The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers

PD-1 regulation in immune homeostasis and immunotherapy

[Progress in Research on Tumor Immune PD-1/PD-L1 Signaling Pathway in Malignant Bone Tumors].

[Research Advances on Programmed Cell Death Receptor-1 Antibody in the Treatment of Lymphoma--Review]

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Regulatory mechanisms of PD-1/PD-L1 in cancers

Application of PD-1 Blockade in Cancer Immunotherapy

Programmed cell death-ligand 2: new insights in cancer

The role of PD-1 signaling in health and immune-related diseases

Cancer cell-intrinsic PD-1: Its role in malignant progression and immunotherapy

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

The role of lncRNAs and circRNAs in the PD-1/PD-L1 pathway in cancer immunotherapy

Non-canonical PD-1 signaling in cancer and its potential implications in clinic